Vivos Therapeutics, Inc. (VVOS) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-15

Key Insights

Vivos Therapeutics, Inc. reported its financial results for the fiscal year ended December 31, 2025 on April 15, 2026, indicating the company's performance over the past year.
The company did not provide any additional details or commentary on the financial results in the 8-K filing, limiting the information available to investors.
Without further details on the company's financial performance, revenue trends, margins, or guidance, it is difficult to assess the significance of this earnings announcement for investors.

Want the newest filings?

This analysis covers the filing from 2026-04-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-01-20

Vivos Therapeutics has entered into a warrant inducement agreement with an institutional investor, providing the company with approximately $4.6 million in gross proceeds from the exercise of outstanding warrants.
As part of the agreement, Vivos will issue new Series A and Series B warrants to the investor, providing additional potential capital in the future.
The company has agreed to file a registration statement to register the resale of the shares underlying the new warrants, and is restricted from certain equity financing activities during a specified period.

Filed: 2026-01-16

Vivos Therapeutics has entered into a $5.5 million unsecured convertible promissory note with its affiliate investor V-Co Investors 3 LLC to support a planned equity financing.
The note includes a 10% original issuance discount and will automatically convert into the equity instruments issued in the planned financing, which may or may not be led by V-Co.
The financing is expected to close by February 16, 2026, and the company has the ability to repay the note without penalty after that date.

Other reports for Vivos Therapeutics, Inc.

Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.